New hope for Hard-to-Treat cancers: targeted immunotherapy trial launches
NCT ID NCT04957615
First seen Oct 31, 2025 · Last updated May 12, 2026 · Updated 23 times
Summary
This study tests whether the immunotherapy drug nivolumab can help control cancer in people with metastatic or inoperable solid tumors that have a specific genetic change (ARID1A mutation) and a protein marker (CXCL13). Sixteen participants will receive nivolumab to boost their immune system's ability to fight the cancer. The goal is to see if the tumors shrink or stop growing, and how long people live.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.